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Benzodipyrroles are aromatic heterocyclic that have elicited considerable interest in 





 and as semiconductive materials.
8,9
 The use of benzodipyrroles has been 
widely explored in the treatment of several kinds of infectious diseases.
3
 In addition, these 
molecules have been seen to serve as effective precursors to porphycenes, which are potential 
photosensitizers for photodynamic therapy. The study of a promising class of 
photosensitizers, called dibenzoporphycenes, has been limited due to their difficult synthesis 
and low solubility.
4
 Hence, the synthesis of new benzodipyrrole for the synthesis of more 
soluble benzoporphycenes is needed. This thesis describes the synthesis and characterization 
of the more soluble dimethoxybenzodipyrrole. The synthesis of methoxy benzodipyrroles 
was straightforward, clean and had a workable level of solubility in organic solvents. 
However, dimethoxy benzodipyrrole was obtained in modest yields (~ 8%). This compound 






 Benzodipyrroles are heterocyclic structures constituted of two pyrroles linked by a 
double bond on one the β-positions and can occur in five possible isomers (cf. Figure 1). 
These molecules were first synthesized in gram scale by Berlin et al. via the reduction of bis-
enamines.
1 
These aromatic molecules have been attracted continued interest for their potential 
applications in various fields, including materials (i.e., electroconductive polymers),
1 
sensors 
(i.e., the creation of anion-selective electrodes),
2
 antitumor agents (i.e., antitumor antibiotic 
CC-1065),
3
 and photodynamic therapy (PDT) (i.e., as part of dibenzoporphycenes).
4,2 
Hence 




Figure 1: Five possible isomers of benzodipyrroles (1-5). 
  
 In 1973, Baxter and coworkers developed the synthesis of benzodipyrroles via 
intermolecular reactions between the quinol 6 and aliphatic primary and secondary amines in 
presence of air and at pH 7 led to the formation of benzodipyrroles 3 (cf. Scheme 1).
5
 
However, this synthetic approach were inefficient and extremely laborious. Later in 1985, 
Sundberg et al. synthesized benzo[1,2-b:4,3-b’]dipyrroles by intramolecular condensation of 
3-(3-pyrrolyl)thiopyrrolidones (cf. Scheme 1).
3
 In the initial study, the thiopyrrolidone 
nitrogen was substituted by a benzyl group. However, the facile dehydrogenation of the 







Scheme 1: a) Synthesis of benzodipyrrole 3 using quinol in presence of air and pH 7.
5
 b) 




Benzodipyrroles as Building Blocks of Sensitizers for Photodynamic Therapy 
 
Photodynamic therapy (PDT) has been successfully used against precancerous and 
cancerous masses, by using photosensitizing drugs. The treatment uses a few key 
components: a localized photosensitizer, or a molecule that is light sensitive, oxygen, and the 
administration of a specific wavelength of light (cf. Figure 2).
7
 Light activation promotes 
radicalization of oxygen species, which causes the destruction of cells only in the particular 
areas of tissue that have been exposed to light.
8
 In 1903, von Tappeiner and Jesionek, used 
PDT to treat skin tumors with topically applied eosin, a fluorescent red dye, and white light.
9
 
Other potential application for PDT is antimicrobial PDT (ADPT), which has been proposed 
as a possible alternative to antibiotic treatment for localized infections.
10
 In this technique, 
photosensitized processes promoted by irradiation of visible light inactivate microbial 
pathogens. However, Gram-negative bacteria were resistant to the photosensitizer interaction. 





 As Gram-negative bacteria are often responsible for severe pathological 








In the quest for the improvement of PDT efficacy more selective and potent 
sensitizers are being developed continually. Among the molecules proposed as potential 
sensitizers are sapphyrins and porphycenes. In particular, the study of these macrocycles that 
are constituted by benzodipyrroles have been of great interest in recent years.
6, 7
 In 2005, Lee 
and coworkers reported the synthesis of a benzodipyrrole-derived sapphyrin 7 which is 
constituted by a benzodipyrrole subunit and tripyrromethane dicarboxylic acid (cf. Figure 3). 
This oligopyrrolic macrocycle exhibited red-shifter absorptions bands, in which the use of the 
benzodipyrrole unit could provide fine tuning of the electronic properties of the macrocycle.
7, 
8 
On the other hand, tetraalkylated dibenzoporphycenes, such as tetra-tert-butyl 
dibenzoporphycene 8 and tetramethyldibenzoporphycene 9 (c.f. Figure 3), have been 
synthesized for potential use in PDT applications.
1, 4
 Unfortunately, these macrocycles have 







     
Figure 3: Benzodipyrrole-derived sapphyrin 7,
6





Biological Properties of Benzodipyrroles 
 
Since the isolation of benzodipyrroles as part of a study of phosphodiesterase 
inhibitors (PDE I and PDE II) by Umezawa and coworkers,
10
 the synthesis and biological 
properties of benzodipyrroles have been widely studied in the development of antitumor 
drugs.
3 
 Phosphodiesterase inhibitors PDE I and PDE II, which contain the benzo[1,2-b:4,3-
b’]dipyrrole ring.  The substitution pattern of the phosphodiesterase was also found in the 
potent antitumor antibiotic CC-1065 produced by Streptomyces zelensis NRRL 11,183 (c.f. 
Figure 4).
3
 This compound was isolated by researchers at The Upjohn Company by Hurley 
and coworkers in 1986 from soil cultures. The X-ray diffraction analysis revealed that CC-
1065 is comprised of three benzodipyrrole subunits (subunits A, B, and C) connected by 
amide bonds.
3
 In this report, CC-1065 displayed both cytotoxic activity against L1210 cells 






Figure 4: Photodiesterase inhibitor PDE I 10, and acetic acid degradation product of CC-
1065 11.
9  
Structure of CC-1065 12.  
 
CC-1065 has several important chemical features, which are crucial in its biological 
role.  It is a structurally and biosynthetically unique antitumor antibiotic that is believed to 
target DNA by bind covalently to DNA through N3 of adenine.  In a study by Li et al., CC-
1065 potency was measured as the degree of drug-induced inhibition of L1210 cell growth.
12 
A strong reduction in CC-1065 potency occurred upon premixing with calf thymus DNA, 
indicative of the weak inhibition of thymidine kinase activity by CC-1065.
 
In addition, the 
right-handed twist along the length of the molecule suggests binding within one of the 
grooves of DNA.  Several hydrophobic and hydrophilic groups are distributed along the 
concave and convex edges of the drug molecule, which is important in aiding binding of CC-
1065 in the minor groove of DNA (cf. Figure 4 Compound 10).  Another observed attribute 
of CC-1065 was its effects on cellular macromolecule synthesis, examined in L1210 cells in 
7 
 
vitro where DNA synthesis was greatly inhibited.  Experimental data showed that CC-1065 
was able to interact with the DNA template, thus inhibiting normal DNA polymerase-α 
activity.   
The antitumor activity of CC-1065 was tested using in vitro transplantable human 
tumor cloning assays by Bhuyan et al.,
13 
It was found that within 1 hour of exposure to 0.1 
ng/ml of the drug, there was a 70% decrease in tumor-colony forming units (T-CFU) 
compared to control plated in 1/9 tumors from lung cancer patients, ½ pancreatic tumors, 1/1 
small bowel tumor, and ½ adenocarcinomas of unknown origin.  Further decreases (>50%) 
were seen in breast, ovarian, pancreatic, stomach and testicular cancers.  Not as significant 
decreased (< 50%) were seen in patients with melanoma, leukemia, esophageal cancer, colon 
cancer, or sarcoma.   
With these developments in benzodipyrrole chemistry in mind, the development of 
more soluble benzodipyrroles was explored. These can serve as a means to develop 
precursors of dibenzoporphycenes. It is been seen that using pyrrole-based research, 
modifications to precursors at the meso-carbon atoms and/or peripheral β-pyrrole carbon 
atoms of strongly electron-withdrawing groups can prevent degeneration.
4
 Addition of 
methoxy groups is predicted to increase solubility of this class of molecules.   
 
Discussion and Results 
 
 The synthesis of dimethoxybenzopyrrole 18 is presented in Scheme 2.  It starts with 
the reaction between morpholine, 3-methyl catechol, and formaldehyde, which afforded 3-
methyl-6-(morpholine methyl)benzene-1,2-diol 13 in 43.4% yield.  3,6-dimethyl-benzene-
1,2-diol 14 was obtained by the reaction of 13 with hydrogen gas and Pt catalyst at 70˚C 
followed by alkylation of the latter compound with dimethylsulfate to produce 2,3-
demethoxy-1,4-dimethylbenzene 15, in 88.7% yield. Subsequent nitration of 15 with 
concentrated nitric acid (70%) afforded 1,2-demethoxy-3,6-dimethyl-4,5-dinitrobenzene 16 
in 36.7% yield.  Dimethoxybisenamine 17 was obtained in 59.0 yield by reacting 16 with 
dimethylformamide diethylacetate under N2 atmosphere. Finally, the formation of 
dimethoxybenzodipyrrole 18 was carried out under hydrogen gas (1 atm) using Pt catalyst to 
obtain 7.6% of the desired product. In an effort to synthesize a tetraformylated 
benzodipyrrole 19 that could be used as precursor for future synthesis of dibenzoporphycene, 
formylation of 18 was carried out by reacting POCl3 in DMF (cf. Scheme 3). Unfortunately, 
8 
 
the tetraformylated derivative of compound 18 could not be isolated. This is attributed to a 









Scheme 3: Proposed synthesis of tetraformylated dimethoxy benzodipyrrole 19. 
 
Conclusion 
 The synthesis of dimethoxy benzodipyrrole 18 yielded a successful formulation of a 
novel methoxy benzodipyrrole. This compound was fully characterized by proton and carbon 
NMR spectroscopy as well as by high-resolution spectrometry. Compound 18 could serve as 
a precursor for the synthesis of more soluble benzoporphycenes. Attempts to obtain the 
tetraformylated dimethoxy dibenzodipyrrole 19 that could be used as precursor for the 
synthesis of a more soluble dibenzoporphycene, were not successful. This was attributed to 
the polymerization of the benzodipyrrole. In the future, further experimentation with this 
precursor should be conducted in order to obtain porphycenes that may be developed as 
9 
 
photosensitizers for photodynamic therapy. Before that stage, various benzoporphycenes 
should be successfully synthesized from methoxy benzodipyrrole and characterized for 
solubility and sensitization to light.   
 
Experimental Synthesis of Dimethoxy Benzodipyrrole  
 
Prior to use, all glassware was soaked in KOH-saturated isopropyl alcohol for ca. 12 
hours, rinsed with water and acetone and thoroughly dried. Dry solvents (dichloromethane, 
tetrahydofuran, methanol, diethyl ether and acetonitrile) were purified by passage through 
Vacuum Atmosphere solvent drying towers. All other chemicals were used as purchased. All 
solutions were stirred magnetically. Nuclear magnetic resonance (NMR) spectra were 
obtained on a Varian Mercury 400 MHz instrument. High-resolution mass spectra were 
obtained at the University of Texas at Austin, Department of Chemistry and Biochemistry, 
Mass Spectrometry Facility.  
 
3-methyl-6-(tetrahydro-2H-pyran-4ylamino) benzene-1,2-diol (13): In a 250 mL round 
bottom flask, morpholine (9.7 mL, 0.1 mol) , added to  3-methylbenzene-1,2-diol, and 
paraformaldehyde (3.34 g, 0.1 mol) were dissolved in 70 mL of isopropanol. This mixture 
was refluxed under vigorous stirring at 75˚C for 2 hours.  The solution was allowed to cool to 
room temperature. A second solution of 3-methyl catechol (14 g, 0.11 mol) in 50 mL of 
isopropanol was added to the flask.  The entire solution was stirred at room temperature for 
72 hours.  Following this, the resulting crude solid was filtered via vacuum filtration with a 
Büchner funnel.  Recrystallization from ethanol yielded 10.3 g (43.4%).  
1
H NMR (400 MHz, 
296 K, CDCl3): δ (ppm) 6.56, 6.54 (d, (J = 0.02 Hz), 1 H), 6.43, 6.41 (d, (J = 0.02 Hz), 1 H), 
3.73 (bs, 3 H), 3.66 (s, 2 H), 2.56 (bs, 3 H), 2.21 (s, 3 H).  
13
C NMR (100.6 MHz, 296 K, 
CDCl3): δ (ppm) 143.67, 142.65, 123.50, 121.12, 118.84, 117.81, 66.87, 61.52, 52.87, 15.34. 




3,6-dimethyl catechol (14):  Morpholine protected 3-methyl catechol (10.3 g, 48 mmol) was 
dissolved in 150 mL ethanol in a 500 mL round bottom flask. Palladium over carbon catalyst 
(3 g, 28.2 mmol) was added and the solution gently stirred and refluxed overnight under 
hydrogen gas atmosphere. The crude was filtered through a pad of celite using a coarse-
porosity fritted filter, followed by repeated washing with methanol until the liquid ran clear.  
10 
 
The solution was transferred to a 150 mL round bottom flask, to which 50 mL of 1% v/v 
hydrochloric acid was added. Vigorous stirring was applied at room temperature for 3.5 
hours. The product was extracted with dichloromethane (3x50 mL) and the organic phase was 
collected. The organic fractions were dried with sodium sulfate and the solution was 
evaporated under reduced pressure. The compound was purified by chromatography in silica 
gel ethyl acetate/hexanes, 1:4) to give 3.86 g (57.9%).  %). 
1
H NMR (400 MHz, 296 K, 
CDCl3): δ (ppm) 6.59 (s, 1 H), 5.00 (s, 1 H), 2.21 (s, 3 H). 
13
C NMR (100.6 MHz, 296 K, 
CDCl3): δ (ppm) 141.67, 121.72, 121.42, 15.31. HR-ESI (m/z): 138.0885 (calc. For 
[C8H10O2]
+1
: 138.0681).  
2,3-dimethoxy-1,4-dimethylbenzene (15): 3,6-dimethyl catechol (3.86 g, 28.4 mmol was 
added to a 250 mL three neck round bottom flask with 39.89 mL 10% w/v sodium hydroxide 
and 11.32 mL dimethyl sulfate.  This solution was refluxed for 1.5 hours at 100˚C. After this 
time, 8.75 mL 40% w/v sodium hydroxide and 5.15 mL dimethyl sulfate was added to the 
mixture and refluxed for 0.5 hours more. After this time, 4.37 mL 40% w/v sodium 
hydroxide and 2.57 mL dimethyl sulfate was added to the flask and the mixture refluxed at 
the same temperature for 1 hour.  The mixture was then cooled at room temperature.  The 
solution was extracted with diethyl ether (2x20 mL).  The organic fractions were washed with 
20 mL water, 15 mL of 10% w/v sodium hydroxide solution, 20 mL of water, and dried with 
sodium sulfate.  The organic solvent was evaporated to obtain an oil of yield: 4.13 g (88.7%).  
1
H NMR (400 MHz, 296 K, CDCl3): δ (ppm) 6.78 (s, 4 H), 3.81 (s, 2 H), 2.21 (s, 2 H).  
13
C 
NMR (100.6 MHz, 296 K, CDCl3): δ (ppm) 125.87, 125.22, 121.34, 60.53, 60.00, 15.56, 




1,2-dimethoxy-3,6-dimethyl-4,5-dinitrobenzene (16): Compound 3 (4.13 g, 25.2 mmol) 
was added to a 250 mL round bottom flask and the mixture was placed in an ice water bath.  
Nitric acid (34.76 mL) was added dropwise under constant stirring.  The ice bath was 
removed and flask transferred to an oil bath. The solution was heated to 70˚C for 4 hours, and 
then allowed to cool at 40˚C. The crude material was poured in 100 mL ice and a saturated 
solution of sodium carbonate was added under stirring. The material was collected by 
filtration to yield 2.24 g (36.7%).  
1
H NMR (400 MHz, 296 K, CDCl3): δ (ppm) 7.24 (s, 2 H), 
3.88 (s, 6 H), 2.27 (s, 6 H).  
13
C NMR (100.6 MHz, 296 K, CDCl3): δ (ppm) 153.33, 125.82, 







(17): In a two neck 250 mL round bottom flask, Compound 4  (2.24 g, 9.2 mmol) and 
dimethylformamide diethyl acetal (9.51 mL) was dissolved in 20 mL dry 
dimethylformamide. The system was kept under nitrogen gas atmosphere.  The solution was 
refluxed under argon for 24 hours at 115˚C. The flask was allowed to cool at room 
temperature, and the remaining solvent evaporated under reduced pressure. The final product 
was recrystallized from diethyl ether until violet crystals yielded 2.0 g (59.0%).  
1
H NMR 
(400 MHz, 296 K, CDCl3): δ (ppm) 7.24, (s, 3 H), 4.76 (d, (J = 0.02 Hz), 2 H), 3.78 (s, 6 H), 
2.81 (s, 12 H).  
13
C NMR (100.6 MHz, 296 K, CDCl3): δ (ppm) 151.33, 146.29, 122.99, 




Methoxy benzodipyrrole (18): In a 250 mL round bottom flask, bisenamine (2 g, 5.5 mmol) 
and Palladium over carbon catalyst (1.7 g) were added in 200 mL of ethyl acetate. The 
mixture was stirred under hydrogen atmosphere (1 atm) for 18 hours. The mixture was 
filtered through a celite pad and with ethyl acetate until the solvent ran clear. The organic 
solvent was evaporated under reduced pressure. The product was purified by chromatography 
in silica gel (ethyl acetate/hexanes, 1:5) to obtain the final product 6, yielding 0.09 g (7.6%).  
1
H NMR (400 MHz, 296 K, CDCl3): δ (ppm) 8.32 (s, 1 H), 7.06 (s, 1 H), 6.70 (s, 1 H), 4.03 
(s, 3 H).  
13
C NMR (100.6 MHz, 296 K, CDCl3): δ (ppm) 138.29, 121.03, 119.66, 118.75, 




Tetramethyl dimethoxy benzodipyrrole (19): In a 100 mL three neck round bottom flask, 
Compound 18 (0.09 g, 0.42 mmol) was dissolved in dry dimethylformamide (10 mL). The 
solution was placed under nitrogen gas with constant stirring at room temperature for 15 
minutes. The solution was cooled using an ice bath and the system was purged with N2.  
Phosphorous oxychloride (0.16 mL, 1.7 mmol) was added dropwise with a syringe under 
nitrogen atmosphere. The solution was kept in an ice bath and stirred for one hour. The 
solution was warmed at room temperature and stirred for another 30 minutes.  Water (10 mL) 
and potassium hydroxide (2 M) solution was added dropwise until the pH of the solution 
became strongly basic.  A precipitate should have appeared at this time, but the resulting 
compound remained soluble in the organic solvent. The organic solvent was evaporated to 
obtain yellow oil, which could not be characterized. The aqueous fractions were evaporated 
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C NMR of Compound 18. 
 
